The European Orthopedic Hip and Knee Implant Markets, 2003-2008
The European orthopedic implants and trauma products market consists of hip, knee, shoulder, and small joint reconstruction and replacements; fracture fixation and bone growth stimulation; bone graft substitutes and growth factors; and bone cements segments. "European Markets for Orthopedic Implants and Trauma Products", a report published in October 2004 by Windhover/Medtech Insight, surveys and forecasts these markets in France, Germany, Italy, Spain, and the UK. Within these countries there is considerable potential for new and innovative technologies such as bone graft substitutes and the use of resorbable implants in trauma. However, medical-based evidence must show added value and improvement in a patient's quality of life before such innovations will be broadly accepted. Meeting health care regulatory authorities' compliance criteria while not burdening health care payers with dramatic increases in reimbursement budgets is viewed as a major driving factor within Europe.
The European orthopedic implants and trauma products market
consists of hip, knee, shoulder, and small joint reconstruction and
replacements; fracture fixation and bone growth stimulation; bone
graft substitutes and growth factors; and bone cements segments.
European Markets for Orthopedic Implants and Trauma
Products, a report published in October 2004 by
Windhover/Medtech Insight, surveys and forecasts these markets in
France, Germany, Italy, Spain, and the United Kingdom.
Within these countries there is considerable potential for new and innovative technologies such as bone graft substitutes and the use...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.